DownloadHi-Res Photo

David A. Braun, MD, PhD

Assistant Professor of Medicine (Medical Oncology), Louis Goodman and Alfred Gilman Yale Scholar

Research & Publications
Biography
News
Locations

Research Summary

Dr. Braun's laboratory integrates experimental and computational approaches to biomedical research and is currently studying mechanisms of response and resistance to immune therapy in kidney cancer.

Extensive Research Description

How do somatic alterations impact response to immunotherapy?
We integrate genomic, transcriptomic, and immunopathologic analyses with demographic and clinical response data to dissect how tumor genetic features contribute to response or resistance to current immunotherapies, with a focus on immune checkpoint inhibitors (for example, see Braun et al, Nature Medicine, 2020 and Braun et al, JAMA Oncology, 2019)

How does the immune microenvironment impact anti-tumor immunity?
The tumor-immune microenvironment is comprised of heterogeneous cell types that may positively or negatively impact anti-tumor immune responses. Our prior work identified key immune cell populations and cellular interaction circuits that were enriched in advanced kidney cancer (see Braun et al, Cancer Cell, 2021). We now aim to utilize single-cell proteogenomic tools to systematically dissect this complex ecosystem and identify candidate immune cell populations and cellular states that impact response or resistance to immune checkpoint inhibitors. Further, we aim to construct patient-derived model systems to enable a mechanistic understanding of these potential determinants of anti-tumor immunity.

What are the target tumor antigens and what are the characteristics of T cells that recognize them?
The heart of antigen-specific anti-tumor immunity is the interaction between the T cell receptor (TCR) expressed on the surface of tumor-infiltrating T cells (TILs) and the peptide-MHC complex, displayed on a tumor cell. However, in renal cell carcinoma (RCC) and many other cancer types, the important tumor antigens and the T cells that recognize them remain largely unknown. We aim to identify relevant tumor antigens that can ultimately enable innovative “precision” approaches to cancer immunotherapies (for example, see our personalized neoantigen vaccine in RCC, NCT02950766, Co-PIs: Braun, Choueiri, Ott)

Coauthors

Research Interests

Antigens; Carcinoma, Renal Cell; Immunotherapy; Cancer Vaccines; Genomics; Tumor Microenvironment; Transcriptome

Selected Publications

1891P Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinomaSaliby R, Jammihal T, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, Zarif T, Ahmar N, Laimon Y, Heng D, Signoretti S, Van Allen E, Choueiri T, Shukla S, Braun D. 1891P Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma. Annals Of Oncology 2023, 34: s1017. DOI: 10.1016/j.annonc.2023.09.1121.
1892P A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)McKay R, Xie W, Leucht K, Jegede O, Braun D, Atkins M, Grimm M, Choueiri T. 1892P A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC). Annals Of Oncology 2023, 34: s1017-s1018. DOI: 10.1016/j.annonc.2023.09.1122.
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer statesNyman J, Denize T, Bakouny Z, Labaki C, Titchen B, Bi K, Hari S, Rosenthal J, Mehta N, Jiang B, Sharma B, Felt K, Umeton R, Braun D, Rodig S, Choueiri T, Signoretti S, Van Allen E. Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states. Cell Reports Medicine 2023, 4: 101189. PMID: 37729872, PMCID: PMC10518628, DOI: 10.1016/j.xcrm.2023.101189.
Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinomaSaliby R, Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, Denize T, Kane M, Madsen K, Ficial M, Hirsch L, Wei X, Steinharter J, Harshman L, Vaishampayan U, Severgnini M, McDermott D, Lee G, Xu W, Van Allen E, McGregor B, Signoretti S, Choueiri T, McKay R, Braun D. Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma. The Oncologist 2023, 28: s15-s16. PMCID: PMC10445571, DOI: 10.1093/oncolo/oyad216.026.
Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC)Saad E, Labaki C, Saliby R, Bakouny Z, Song L, Wall M, Pan W, Semaan K, Eid M, Gwo-Shu M, Braun D, Liu X, Choueiri T. Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC). The Oncologist 2023, 28: s4-s5. PMCID: PMC10445570, DOI: 10.1093/oncolo/oyad216.007.
Characterization of the Cellular Origin and Oncogenic Mechanisms of Chromophobe Renal Cell Carcinoma (ChRCC) and Renal Oncocytic NeoplasmsLabaki C, Al-Choueiry M, Nyman J, Hou Y, Bi K, Zhang L, Hobeika C, Bakouny Z, Priolo C, Khabibullin D, Schindler N, Fu J, Camp S, Saliby R, Saad E, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Characterization of the Cellular Origin and Oncogenic Mechanisms of Chromophobe Renal Cell Carcinoma (ChRCC) and Renal Oncocytic Neoplasms. The Oncologist 2023, 28: s7-s8. PMCID: PMC10445568, DOI: 10.1093/oncolo/oyad216.011.
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastasesSchoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.
Abstract PR015: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinomaBraun D, Keskin D, Shukla S, McGregor B, Schindler N, Blass E, Klaeger S, Pomerance L, Sarkizova S, Li S, Southard J, Moranzoni G, Pedersen C, Liu Y, Chang S, Hirsch M, LeBoeuf N, Mossanen M, Chea V, Carulli I, Olive O, Mehndiratta A, Greenslade H, Oliveira G, Iorgulescu J, Signoretti S, Aster J, Elagina L, Leshchiner I, Getz G, Harden M, Gabriel S, Olsen L, Neuberg D, Fritsch E, Hacohen N, Livak K, Carr S, Ott P, Wu C, Choueiri T. Abstract PR015: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinoma. Cancer Research 2023, 83: pr015-pr015. DOI: 10.1158/1538-7445.kidney23-pr015.
Abstract B019: Clinical and molecular characterization of chromophobe renal cell carcinoma: A focus on immunotherapy based regimens and the tumor immune microenvironmentAlchoueiry M, Labaki C, Zhang L, Hou Y, Bi K, Hobeika C, Wells J, Takemura K, Bakouny Z, Camp S, Priolo C, Khabibullin D, Schindler N, Saliby R, Saad E, Salem S, Daou M, McKay R, Pal S, Heng D, Van Allen E, Shukla S, Choueiri T, Braun D, Henske E. Abstract B019: Clinical and molecular characterization of chromophobe renal cell carcinoma: A focus on immunotherapy based regimens and the tumor immune microenvironment. Cancer Research 2023, 83: b019-b019. DOI: 10.1158/1538-7445.kidney23-b019.
Abstract A029: Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC)Semaan K, Zarif T, Eid M, Shah V, Fortunato B, Saliby R, Nassar A, Alaiwi S, Seo J, Labaki C, Bakouny Z, Matar S, Ahmar N, Laimon Y, Lee G, Pomerantz M, Berchuck J, Signoretti S, Van Allen E, Choueiri T, Braun D, Freedman M, Baca S. Abstract A029: Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC). Cancer Research 2023, 83: a029-a029. DOI: 10.1158/1538-7445.kidney23-a029.
Abstract A013: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinomaBraun D, Keskin D, Shukla S, McGregor B, Schindler N, Blass E, Klaeger S, Pomerance L, Sarkizova S, Li S, Southard J, Moranzoni G, Pedersen C, Liu Y, Chang S, Hirsch M, LeBoeuf N, Mossanen M, Chea V, Carulli I, Olive O, Mehndiratta A, Greenslade H, Oliveira G, Iorgulescu J, Signoretti S, Aster J, Elagina L, Leshchiner I, Getz G, Harden M, Gabriel S, Olsen L, Neuberg D, Fritsch E, Hacohen N, Livak K, Carr S, Ott P, Wu C, Choueiri T. Abstract A013: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinoma. Cancer Research 2023, 83: a013-a013. DOI: 10.1158/1538-7445.kidney23-a013.
Abstract B013: T cell clonotype expansion is common in advanced renal cell carcinoma but is not associated with altered response to PD-1 blockadeHugaboom M, Ruthen N, Jegede O, Schindler N, Wirth L, Kyrysyuk S, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D, Street K. Abstract B013: T cell clonotype expansion is common in advanced renal cell carcinoma but is not associated with altered response to PD-1 blockade. Cancer Research 2023, 83: b013-b013. DOI: 10.1158/1538-7445.kidney23-b013.
Antigenic targets in clear cell renal cell carcinomaSchindler N, Braun D. Antigenic targets in clear cell renal cell carcinoma. Kidney Cancer 2023, 7: 81-91. PMID: 38014393, PMCID: PMC10475986, DOI: 10.3233/kca-230006.
Chromophobe renal cell carcinomaHenske E, Cheng L, Hakimi A, Choueiri T, Braun D. Chromophobe renal cell carcinoma. Cancer Cell 2023, 41: 1383-1388. PMID: 37541245, DOI: 10.1016/j.ccell.2023.07.006.
Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell CarcinomaLabaki C, Saliby R, Bakouny Z, Saad E, Semaan K, Eid M, Lalani A, Choueiri T, Braun D. Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 937-942. PMID: 37407357, DOI: 10.1016/j.hoc.2023.05.021.
Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapiesAnderson K, Braun D, Buqué A, Gitto S, Guerriero J, Horton B, Keenan B, Kim T, Overacre-Delgoffe A, Ruella M, Triplett T, Veeranki O, Verma V, Zhang F. Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Journal For ImmunoTherapy Of Cancer 2023, 11: e006533. PMID: 37399356, PMCID: PMC10314654, DOI: 10.1136/jitc-2022-006533.
Novel Immune Therapies for Renal Cell Carcinoma Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 AxesSaad E, Saliby R, Labaki C, Xu W, Viswanathan S, Braun D, Bakouny Z. Novel Immune Therapies for Renal Cell Carcinoma Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes. Hematology/Oncology Clinics Of North America 2023, 37: 1027-1040. PMID: 37391289, DOI: 10.1016/j.hoc.2023.05.023.
Novel Targeted Therapies for Renal Cell Carcinoma Building on the Successes of Vascular Endothelial Growth Factor and mTOR InhibitionSaliby R, Saad E, Labaki C, Xu W, Braun D, Viswanathan S, Bakouny Z. Novel Targeted Therapies for Renal Cell Carcinoma Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition. Hematology/Oncology Clinics Of North America 2023, 37: 1015-1026. PMID: 37385938, DOI: 10.1016/j.hoc.2023.05.022.
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma.Saliby R, El Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, Denize T, Kane M, Madsen K, Ficial M, Hirsch L, Wei X, Steinharter J, Harshman L, Vaishampayan U, Severgnini M, McDermott D, Lee G, Xu W, Van Allen E, McGregor B, Signoretti S, Choueiri T, McKay R, Braun D. Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma. Cancer Immunology Research 2023, 11: 1114-1124. PMID: 37279009, PMCID: PMC10526700, DOI: 10.1158/2326-6066.cir-22-0996.
Characterization of the immunophenotype and tumor specificity of CD8+ T-cells in chromophobe renal cell carcinoma (ChRCC) and renal oncocytic neoplasms.Labaki C, Hobeika C, Hou Y, Zhang L, Bi K, Bakouny Z, Camp S, Priolo C, Khabibullin D, Schindler N, Alchoueiry M, Denize T, Saliby R, Matar S, Signoretti S, Van Allen E, Shukla S, Henske E, Choueiri T, Braun D. Characterization of the immunophenotype and tumor specificity of CD8+ T-cells in chromophobe renal cell carcinoma (ChRCC) and renal oncocytic neoplasms. Journal Of Clinical Oncology 2023, 41: 4558-4558. DOI: 10.1200/jco.2023.41.16_suppl.4558.
Association of host immune signatures with response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC).Saad E, Labaki C, Saliby R, Song L, Bakouny Z, Pan W, Wall M, Lee G, Braun D, Liu X, Choueiri T. Association of host immune signatures with response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2023, 41: 4550-4550. DOI: 10.1200/jco.2023.41.16_suppl.4550.
Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.El Ahmar N, Matar S, Jegede O, Savla V, Bagheri Sheshdeh A, Ghandour F, Denize T, West D, Choueiri T, Catalano P, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial. Journal Of Clinical Oncology 2023, 41: 4549-4549. DOI: 10.1200/jco.2023.41.16_suppl.4549.
Immune landscape of patients with metastatic non-clear cell renal cell carcinoma (nccRCC) treated with atezolizumab plus bevacizumab.Saliby R, El Zarif T, Bakouny Z, Xie W, Flippot R, Denize T, Shah V, Kane H, Madsen K, Harshman L, Vaishampayan U, McDermott D, Lee G, Xu W, Van Allen E, McGregor B, Signoretti S, Choueiri T, McKay R, Braun D. Immune landscape of patients with metastatic non-clear cell renal cell carcinoma (nccRCC) treated with atezolizumab plus bevacizumab. Journal Of Clinical Oncology 2023, 41: 4535-4535. DOI: 10.1200/jco.2023.41.16_suppl.4535.
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).McGregor B, Huang J, Xie W, Xu W, Bilen M, Braun D, Zhang T, McKay R, McDermott D, Hammers H, Choueiri T. Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh). Journal Of Clinical Oncology 2023, 41: 4520-4520. DOI: 10.1200/jco.2023.41.16_suppl.4520.
Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Labaki C, Bakouny Z, Lemelin A, Ernst M, Takemura K, Wells J, Pal S, Szabados B, Beuselinck B, McKay R, Lee J, Yuasa T, Parnis F, Bjarnason G, McGregor B, Braun D, Xie W, Xu W, Heng D, Choueiri T. Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2023, 41: 4519-4519. DOI: 10.1200/jco.2023.41.16_suppl.4519.
Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.Braun D, Street K, Jegede O, Ruthen N, Hugaboom M, Schindler N, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C. Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study. Journal Of Clinical Oncology 2023, 41: 4524-4524. DOI: 10.1200/jco.2023.41.16_suppl.4524.
Immunobiology and Metabolic Pathways of Renal Cell CarcinomaBraun D, Chakraborty A. Immunobiology and Metabolic Pathways of Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 827-840. PMID: 37246090, DOI: 10.1016/j.hoc.2023.04.012.
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Signoretti S, Denize T, Cimadamore A, Wu C, Braun D, Einstein D, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal For ImmunoTherapy Of Cancer 2023, 11: e004780. PMID: 36948504, PMCID: PMC10040058, DOI: 10.1136/jitc-2022-004780.
The Changing Landscape of Immunotherapy for Advanced Renal CancerKashima S, Braun D. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urologic Clinics Of North America 2023, 50: 335-349. PMID: 36948676, DOI: 10.1016/j.ucl.2023.01.012.
Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens.Labaki C, Bakouny Z, Wells J, Takemura K, Saliby R, Meza L, Gebrael G, Porta C, Lee J, Basappa N, De Velasco G, McKay R, Pal S, Agarwal N, Donskov F, Braun D, Henske E, Xie W, Heng D, Choueiri T. Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens. Journal Of Clinical Oncology 2023, 41: 654-654. DOI: 10.1200/jco.2023.41.6_suppl.654.
Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC).Choueiri T, Motzer R, Powles T, Burotto M, Apolo A, Escudier B, Tomita Y, McDermott D, Braun D, Han C, Lee G, Dwivedi B, Vemula S, Li J, Fedorov V, Gupta S. Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC). Journal Of Clinical Oncology 2023, 41: 608-608. DOI: 10.1200/jco.2023.41.6_suppl.608.
Examination of resistance to nivolumab monotherapy through single-cell analysis of tumors from patients enrolled in the HCRN GU16-260 study of nivolumab monotherapy.Braun D, Street K, Jegede O, Ruthen N, Hugaboom M, Schindler N, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C. Examination of resistance to nivolumab monotherapy through single-cell analysis of tumors from patients enrolled in the HCRN GU16-260 study of nivolumab monotherapy. Journal Of Clinical Oncology 2023, 41: 698-698. DOI: 10.1200/jco.2023.41.6_suppl.698.
35 Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic GvHD and Candidate Gvl TargetsCieri N, Hookeri N, Stromhaug K, Stevens J, Kooshesh K, Ji H, Klaeger S, Clauser K, Sarkizova S, Braun D, Penter L, Oliveira G, Kim H, Lane W, Li S, Livak K, Ho V, Ritz J, Soiffer R, Keskin D, Stewart C, Gusev A, Getz G, Wu C. 35 Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic GvHD and Candidate Gvl Targets. Transplantation And Cellular Therapy 2023, 29: s30. DOI: 10.1016/s2666-6367(23)00104-5.
Epigenomic charting and functional annotation of risk loci in renal cell carcinomaNassar A, Abou Alaiwi S, Baca S, Adib E, Corona R, Seo J, Fonseca M, Spisak S, El Zarif T, Tisza V, Braun D, Du H, He M, Flaifel A, Alchoueiry M, Denize T, Matar S, Acosta A, Shukla S, Hou Y, Steinharter J, Bouchard G, Berchuck J, O’Connor E, Bell C, Nuzzo P, Mary Lee G, Signoretti S, Hirsch M, Pomerantz M, Henske E, Gusev A, Lawrenson K, Choueiri T, Kwiatkowski D, Freedman M. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. Nature Communications 2023, 14: 346. PMID: 36681680, PMCID: PMC9867739, DOI: 10.1038/s41467-023-35833-5.
Germline variants associated with toxicity to immune checkpoint blockadeGroha S, Alaiwi S, Xu W, Naranbhai V, Nassar A, Bakouny Z, El Zarif T, Saliby R, Wan G, Rajeh A, Adib E, Nuzzo P, Schmidt A, Labaki C, Ricciuti B, Alessi J, Braun D, Shukla S, Keenan T, Van Allen E, Awad M, Manos M, Rahma O, Zubiri L, Villani A, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl K, Freedman M, Choueiri T, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. Nature Medicine 2022, 28: 2584-2591. PMID: 36526723, PMCID: PMC10958775, DOI: 10.1038/s41591-022-02094-6.
Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL TargetsCieri N, Hookeri N, Stromhaug K, Stevens J, Kooshesh K, Klaeger S, Clauser K, Sarkizova S, Braun D, Penter L, Oliveira G, Kim H, Lane W, Li S, Livak K, Ho V, Ritz J, Soiffer R, Keskin D, Stewart C, Gusev A, Getz G, Wu C. Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL Targets. Blood 2022, 140: 4762-4764. DOI: 10.1182/blood-2022-162841.
115 Spatial dissection of T cell clonotype identity, transcriptional profiles, and cell-cell interactions in the tumor microenvironment and tertiary lymphoid structuresIorgulescu B, Liu S, Li S, Borji M, Barrera-Lopez I, Shanmugam V, Lyu H, Morriss J, Garcia Z, Murray E, Reardon D, Yoon C, Braun D, Livak K, Wu C, Chen F. 115 Spatial dissection of T cell clonotype identity, transcriptional profiles, and cell-cell interactions in the tumor microenvironment and tertiary lymphoid structures. 2022, a127-a127. DOI: 10.1136/jitc-2022-sitc2022.0115.
Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune responseLiu S, Iorgulescu J, Li S, Borji M, Barrera-Lopez I, Shanmugam V, Lyu H, Morriss J, Garcia Z, Murray E, Reardon D, Yoon C, Braun D, Livak K, Wu C, Chen F. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity 2022, 55: 1940-1952.e5. PMID: 36223726, PMCID: PMC9745674, DOI: 10.1016/j.immuni.2022.09.002.
252P Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experienceLabaki C, Bakouny Z, Sanglier T, Schmidt A, Shim J, Braun D, Bouquet F, Joyce M, Xie W, Tolaney S, Choueiri T. 252P Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience. Annals Of Oncology 2022, 33: s652. DOI: 10.1016/j.annonc.2022.07.291.
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.Denize T, Hou Y, Pignon J, Walton E, West D, Freeman G, Braun D, Wu C, Gupta S, Motzer R, Atkins M, McDermott D, Choueiri T, Shukla S, Signoretti S. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research 2022, 28: 4045-4055. PMID: 35802667, PMCID: PMC9481706, DOI: 10.1158/1078-0432.ccr-22-0923.
Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center.Saliby R, Labaki C, Xie W, Nonato T, Schmidt A, Bakouny Z, Xu W, Ravi P, Braun D, Hirsch M, McKay R, Choueiri T, McGregor B. Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center. Journal Of Clinical Oncology 2022, 40: e16522-e16522. DOI: 10.1200/jco.2022.40.16_suppl.e16522.
Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.Xu W, Bharadwaj M, Birch G, Schindler N, Labaki C, Saliby R, Bakouny Z, Freeman D, O'Toole J, Lee G, McGregor B, Hirsch M, Shukla S, McDermott D, Signoretti S, Romee R, Choueiri T, Braun D. Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes. Journal Of Clinical Oncology 2022, 40: e16521-e16521. DOI: 10.1200/jco.2022.40.16_suppl.e16521.
Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.Labaki C, Bakouny Z, Sanglier T, Schmidt A, Shim J, Braun D, Bouquet F, Joyce M, Xie W, Tolaney S, Choueiri T. Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience. Journal Of Clinical Oncology 2022, 40: 6520-6520. DOI: 10.1200/jco.2022.40.16_suppl.6520.
Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms.Labaki C, Zhang L, Hou Y, Bi K, Hobeika C, Bakouny Z, Camp S, Priolo C, Khabibullin D, Schindler N, Alchoueiry M, Denize T, Saliby R, Matar S, Signoretti S, Van Allen E, Shukla S, Braun D, Henske E, Choueiri T. Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms. Journal Of Clinical Oncology 2022, 40: 4549-4549. DOI: 10.1200/jco.2022.40.16_suppl.4549.
Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.Saliby R, Jammihal T, Labaki C, Xie W, Motzer R, Powles T, Rini B, Albiges L, Pal S, McKay R, Signoretti S, Shukla S, Van Allen E, Braun D, Choueiri T. Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience. Journal Of Clinical Oncology 2022, 40: 4531-4531. DOI: 10.1200/jco.2022.40.16_suppl.4531.
Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.Adib E, Nassar A, El Zarif T, Kale N, Rakaee M, Mouhieddine T, Abou Alaiwi S, Freeman D, Labban M, Akl E, Haddad R, Hodi F, Sonpavde G, Giannakis M, Braun D, Gusev A, Choueiri T, Overstreet E, Stone E, Kwiatkowski D. Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors. Journal Of Clinical Oncology 2022, 40: 2622-2622. DOI: 10.1200/jco.2022.40.16_suppl.2622.
Landscape of helper and regulatory antitumour CD4+ T cells in melanomaOliveira G, Stromhaug K, Cieri N, Iorgulescu J, Klaeger S, Wolff J, Rachimi S, Chea V, Krause K, Freeman S, Zhang W, Li S, Braun D, Neuberg D, Carr S, Livak K, Frederick D, Fritsch E, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Yoon C, Keskin D, Ott P, Rodig S, Boland G, Wu C. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature 2022, 605: 532-538. PMID: 35508657, PMCID: PMC9815755, DOI: 10.1038/s41586-022-04682-5.
Spatially mapping T cell receptors and transcriptomesLiu S, Iorgulescu J, Li S, Barrera-Lopez I, Borji M, Shanmugam V, Morriss J, Garcia Z, Murray E, Braun D, Livak K, Wu C, Chen F. Spatially mapping T cell receptors and transcriptomes. The Journal Of Immunology 2022, 208: 172.01-172.01. DOI: 10.4049/jimmunol.208.supp.172.01.
Tumor-Infiltrating T Cells — A PortraitBraun DA, Wu CJ. Tumor-Infiltrating T Cells — A Portrait. New England Journal Of Medicine 2022, 386: 992-994. PMID: 35263526, DOI: 10.1056/nejmcibr2119477.
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Signoretti S, Denize T, Cimadamore A, Braun D, Wu C, Einstein D, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report. Journal Of Clinical Oncology 2022, 40: 288-288. DOI: 10.1200/jco.2022.40.6_suppl.288.
655 Landscape of helper and regulatory CD4+ T cells in melanomaOliveira G, Stromhaug K, Klaeger S, Cieri N, Iorgulescu B, Li S, Braun D, Neuberg D, Carr S, Livak K, Tompers D, Fritsch E, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Keskin D, Ott P, Rodig S, Boland G, Wu C. 655 Landscape of helper and regulatory CD4+ T cells in melanoma. Journal For ImmunoTherapy Of Cancer 2021, 9: a684-a684. DOI: 10.1136/jitc-2021-sitc2021.655.
76 Spatial mapping of T cell receptors and transcriptomes in renal cell carcinoma following immune checkpoint inhibitor therapyLiu S, Iorgulescu B, Li S, Morriss J, Borji M, Murray E, Braun D, Livak K, Wu C, Chen F. 76 Spatial mapping of T cell receptors and transcriptomes in renal cell carcinoma following immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2021, 9: a84-a85. DOI: 10.1136/jitc-2021-sitc2021.076.
Resident-Reported Impact of a Novel Oncology Curriculum for Internal Medicine ResidentsTsai F, Guercio B, Stuver S, Stern R, Peluso M, Winkler M, Piawah S, Vallurupalli M, Luskin M, Braun D, Parent A, Glotzbecker B, Kilbridge K. Resident-Reported Impact of a Novel Oncology Curriculum for Internal Medicine Residents. Journal Of Cancer Education 2021, 37: 1879-1885. PMID: 34480712, PMCID: PMC8417651, DOI: 10.1007/s13187-021-02055-6.
Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC)Wang Y, Buck A, Grimaud M, Kodangattil S, Razimbaud C, Fayed A, Chang M, Culhane A, Braun D, Choueiri T, Wu C, Wei K, Chan L, Piel B, Ivanova E, Paweletz C, Barbie D, Jennings R, Ficial M, Sticco-Ivins M, Signoretti S, Freeman G, Zhu Q, Marasco W. Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC). Cancer Research 2021, 81: 62-62. DOI: 10.1158/1538-7445.am2021-62.
Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH).McGregor B, Xie W, Bilen M, Braun D, Xu W, Ravi P, Heath E, McDermott D, McKay R, Hammers H, Choueiri T. Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH). Journal Of Clinical Oncology 2021, 39: tps4592-tps4592. DOI: 10.1200/jco.2021.39.15_suppl.tps4592.
Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC).Labaki C, Alaiwi S, Schmidt A, Zarif T, Bakouny Z, Nuzzo P, Xu W, Braun D, McGregor B, Choueiri T. Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC). Journal Of Clinical Oncology 2021, 39: 4583-4583. DOI: 10.1200/jco.2021.39.15_suppl.4583.
Achieve clear cell renal cell carcinoma (CCRCC) cures through dual-targeted fine-tuned immune restoring (DFIR) CAR-T cell therapyWang Y, Buck A, Grimaud M, Kodangattil S, Razimbaud C, Fayed A, Chang M, Culhane A, Braun D, Choueiri T, Wu C, Wei K, Chan L, Piel B, Ivanova E, Paweletz C, Barbie D, Jenning R, Ficial M, Sticco-Ivins M, Signoretti S, Freeman G, Zhu Q, Marasco W. Achieve clear cell renal cell carcinoma (CCRCC) cures through dual-targeted fine-tuned immune restoring (DFIR) CAR-T cell therapy. Cytotherapy 2021, 23: s93. DOI: 10.1016/s1465324921004126.
Progressive immune dysfunction with advancing disease stage in renal cell carcinomaBraun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 2021, 39: 632-648.e8. PMID: 33711273, PMCID: PMC8138872, DOI: 10.1016/j.ccell.2021.02.013.
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinomaBraun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, Choueiri TK. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology 2021, 18: 199-214. PMID: 33437048, PMCID: PMC8317018, DOI: 10.1038/s41571-020-00455-z.
Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockadeLi H, Bullock K, Gurjao C, Braun D, Shukla S, Bosse D, Lalani A, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott D, Freeman G, Van Allen E, Schreiber S, Hodi F, Sellers W, Garraway L, Clish C, Choueiri T, Giannakis M. Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Cancer Research 2020, 80: ng13-ng13. DOI: 10.1158/1538-7445.am2020-ng13.
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinomaBraun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, Choueiri TK. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine 2020, 26: 909-918. PMID: 32472114, PMCID: PMC7499153, DOI: 10.1038/s41591-020-0839-y.
Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.Ficial M, Jegede O, Sant'Angelo M, Moreno S, Braun D, Wind-Rotolo M, Pignon J, Catalano P, Sun M, Van Allen E, Freeman G, Sharpe A, Hodi F, Motzer R, Wu C, Atkins M, McDermott D, Shukla S, Choueiri T, Signoretti S. Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial. Journal Of Clinical Oncology 2020, 38: 5023-5023. DOI: 10.1200/jco.2020.38.15_suppl.5023.
Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.Braun D, Hou Y, Bakouny Z, Ficial M, Sant'Angelo M, Ross-Macdonald P, Jegede O, Sun M, Wind-Rotolo M, Pignon J, Neuberg D, Catalano P, Freeman G, Sharpe A, McDermott D, Van Allen E, Signoretti S, Wu C, Shukla S, Choueiri T. Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade. Journal Of Clinical Oncology 2020, 38: 5010-5010. DOI: 10.1200/jco.2020.38.15_suppl.5010.
Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE).McKay R, Xie W, McGregor B, Braun D, Wei X, Kyriakopoulos C, Zakharia Y, Maughan B, Rose T, Stadler W, McDermott D, Harshman L, Choueiri T. Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE). Journal Of Clinical Oncology 2020, 38: 5005-5005. DOI: 10.1200/jco.2020.38.15_suppl.5005.
Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.Flippot R, Bakouny Z, Wei X, Braun D, McGregor B, Steinharter J, Harshman L, Vaishampayan U, Severgnini M, McDermott D, Hodi F, Lee G, Van Allen E, Signoretti S, Choueiri T, McKay R. Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial. Journal Of Clinical Oncology 2020, 38: 740-740. DOI: 10.1200/jco.2020.38.6_suppl.740.
Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer.Mahoney K, Ross-Macdonald P, Shukla S, Braun D, Song L, Veras E, Wind-Rotolo M, Van Allen E, McDermott D, Hodi F, Choueiri T, Freeman G. Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer. Journal Of Clinical Oncology 2020, 38: 746-746. DOI: 10.1200/jco.2020.38.6_suppl.746.
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).Bakouny Z, Braun D, Shukla S, Pan W, Gao X, Hou Y, Flaifel A, Nassar A, Abou Alaiwi S, Flippot R, Steinharter J, Nuzzo P, Ishii Y, Ross-Macdonald P, Lee G, McDermott D, Heng D, Signoretti S, Van Allen E, Choueiri T. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI). Journal Of Clinical Oncology 2020, 38: 715-715. DOI: 10.1200/jco.2020.38.6_suppl.715.
Safety and efficacy of retreatment with immune checkpoint inhibitors (ICIs) in patients with metastatic RCC (mRCC) who have previously received an ICI.Ravi P, Bakouny Z, Flippot R, Braun D, Abou Alaiwi S, Wei X, McGregor B, Kilbridge K, Choudhury A, Harshman L, Choueiri T. Safety and efficacy of retreatment with immune checkpoint inhibitors (ICIs) in patients with metastatic RCC (mRCC) who have previously received an ICI. Journal Of Clinical Oncology 2020, 38: 698-698. DOI: 10.1200/jco.2020.38.6_suppl.698.
Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).Pignon J, Jegede O, Shukla S, Braun D, Horak C, Wind-Rotolo M, Ishii Y, Catalano P, Freeman G, Jennings R, De Cubas A, Rathmell K, Choueiri T, Atkins M, McDermott D, Signoretti S. Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). Journal Of Clinical Oncology 2019, 37: 4568-4568. DOI: 10.1200/jco.2019.37.15_suppl.4568.
Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).Bakouny Z, Vokes N, Gao X, Nassar A, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter J, Nuzzo P, Pan W, Flaifel A, Lee G, Braun D, Wei X, Signoretti S, McGregor B, Harshman L, Van Allen E, Choueiri T. Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2019, 37: 4514-4514. DOI: 10.1200/jco.2019.37.15_suppl.4514.
Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).Abou Alaiwi S, Nassar A, El Bakouny Z, Berchuck J, Nuzzo P, Flippot R, Flaifel A, Steinharter J, Baca S, Margolis C, Vokes N, Du H, Shukla S, Braun D, Signoretti S, Sonpavde G, Kwiatkowski D, Van Allen E, Choueiri T. Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs). Journal Of Clinical Oncology 2019, 37: 103-103. DOI: 10.1200/jco.2019.37.15_suppl.103.
Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).McKay R, McGregor B, Gray K, Steinharter J, Walsh M, Braun D, Flaifel A, VanAllen E, Wei X, Signoretti S, Harshman L, Vaishampayan U, Choueiri T. Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC). Journal Of Clinical Oncology 2019, 37: 548-548. DOI: 10.1200/jco.2019.37.7_suppl.548.
State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy EraBakouny Z, Flippot R, Braun D, Lalani A, Choueiri T. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus 2019, 6: 37-40. PMID: 30827939, DOI: 10.1016/j.euf.2019.02.014.
Acquired mechanisms of immune escape in cancer following immunotherapyIorgulescu J, Braun D, Oliveira G, Keskin D, Wu C. Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Medicine 2018, 10: 87. PMID: 30466478, PMCID: PMC6249768, DOI: 10.1186/s13073-018-0598-2.
LBA34 PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trialsChoueiri T, Flaifel A, Xie W, Braun D, Ficial M, Jennings R, Nassar A, Escudier B, George D, Motzer R, Morris M, Powles T, Wang E, Huang Y, Freeman G, Signoretti S. LBA34 PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials. Annals Of Oncology 2018, 29: viii726. DOI: 10.1093/annonc/mdy424.040.
Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study.Wei X, McKay R, Gray K, Stadler W, McDermott D, McGregor B, Agarwal N, Kyriakopoulos C, Carneiro B, Rose T, Zakharia Y, Braun D, Livak K, Wu C, Van Allen E, Signoretti S, Lang J, Hodi F, Choueiri T, Harshman L. Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. Journal Of Clinical Oncology 2018, 36: tps4600-tps4600. DOI: 10.1200/jco.2018.36.15_suppl.tps4600.
Antigen Discovery and Therapeutic Targeting in Hematologic MalignanciesBraun D, Wu C. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. The Cancer Journal 2017, 23: 115-124. PMID: 28410299, PMCID: PMC5856170, DOI: 10.1097/ppo.0000000000000257.
Genomic Approaches to Understanding Response and Resistance to ImmunotherapyBraun D, Burke K, Van Allen E. Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clinical Cancer Research 2016, 22: 5642-5650. PMID: 27698000, PMCID: PMC5135569, DOI: 10.1158/1078-0432.ccr-16-0066.

Clinical Trials

Conditions	Study Title
Kidney; Melanoma, skin	A Multicenter Phase 2 Trial to Evaluate Intracranial Response to Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Who Are Anti-PD1/PD-L1 Experienced
Phase I	A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, PK, PD, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients With Relapsed or Refractory Solid Tumors
Melanoma, skin	A Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma

Edit Profile

David A. Braun, MD, PhD

Contact Information

Lab Location

Mailing Address

Patient Care

Research & Publications

Biography

News

Locations